Evaluation of the Sofia SARS Antigen FIA Assay for COVID-19

Study Overview
=================
Brief Summary
-----------------
Evaluating the performance of the Sofia SARS Antigen FIA

Detailed Description
-----------------
RT-PCR is the reference technique for the diagnosis of COVID-19, as recommended by WHO, ECDC and the HAS College. Serological tests to identify antibodies developed by the immune system following infection with SARS-CoV-2 are not currently recommended as a first-line test for the initial diagnosis of COVID-19. However, they can be used in cases of negative RT-PCR and suggestive clinical presentation, or as a salvage test when RT-PCR could not be performed within 7 days of symptom onset. Antigenic tests for the detection of SARS-CoV-2 can be used as a first-line test on nasopharyngeal swabs up to and including 4 days after the onset of symptoms. From the 5th day, only detection by gene amplification is indicated. Given their excellent specificity and the current pandemic situation, it is not necessary to confirm positives with a gene amplification test. However, it is recommended to perform a gene amplification test when the antigenic test result is negative or uninterpretable in symptomatic patients older than 65 years or with at least one risk factor for severe COVID-19. For contact persons detected in isolation or in clusters, it is also possible to use antigenic tests in the following cases as soon as possible and then at 7 days for high-risk contacts (within the same household as an infected patient) ; 7 days after exposure for other contacts (low risk). Given the rapidity of antigenic test results (15 to 30 minutes), the good performance of the Sofia SARS Antigen FIA test in target populations and its traceability, it could be used as a first-line test in emergency rooms and screening centers and thus have a positive impact on the management of ambulatory patients and, by corollary, on viral transmission.

Official Title
-----------------
Evaluation du Test  Sofia SARS Antigen FIA Assay  Dans le Cadre du dépistage de la COVID-19

Conditions
-----------------
SARS-CoV2 Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patient (> or = 18 years of age) Patient with symptoms of COVID-19 (Rhinitis, throat pain, nasal congestion or other signs of local manifestation of the disease in the upper respiratory tract, including loss of taste, with or without additional systemic symptoms such as fatigue, fever, muscle pain...) whose health condition does not require hospitalization (mild to moderate disease) Patient with these symptoms for 5 days or less with a median of 3 to 4 days. Patient with consent to participate in the study Exclusion Criteria: Patient with an age below 18 years Patient under legal protection (guardianship, curatorship) Patient without upper respiratory tract symptoms Patients with symptoms for more than 5 days Patient with previous COVID-19 diagnosed by RT-PCR Patient vaccinated against SARS-CoV-2 (1 or 2 injections) Hospitalized patient Refusal to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| assessment Vs gold standard | PCR results and Ct values for specimens tested are collected and compared with Sofia results. | Up to 35 positive PCR | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
EIA, SARS-CoV2 Infection, Assessment, Diagnosis